



Improving life for people with allergies

STALLERGENES  GREER

Life beyond allergy



- 04 Chairman’s message
Stefan Meister
- 06 Interview
with our CEO
Michele Antonelli



About us

- 12 At a glance
- 14 Our purpose,
our ambition
- 15 Our strategy
- 16 Governance
- 18 People & culture
- 20 Business environment



Serving
patients with
allergies

- 28 Respiratory allergy
patient journey
- 30 Food allergy
patient journey
- 32 Science
- 36 Technical operations



Operating
review

- 42 Europe &
International
- 46 North America
- 50 France



Impact

- 56 Stallergenes Greer
Foundation
- 60 Care beyond allergy



Products
& portfolio

- 66 Products
- 68 Our portfolio

A full-page portrait of Stefan Meister, the Chairman of Stallergenes Greer. He is a middle-aged man with short, light-colored hair, wearing glasses, a dark blue suit, a white shirt, and a patterned blue tie. He is standing in front of a dark, textured wall with a window featuring white blinds on the left. The lighting is soft, highlighting his face and suit. A semi-transparent dark blue box is overlaid at the bottom of the image, containing his name and title in white text.

Stefan Meister

Chairman

2023 was a landmark year for Stallergenes Greer. The Group continued to fulfil its mission of improving the quality of life of people with allergies while creating sustainable growth.

Throughout the year, Stallergenes Greer made significant progress on its strategic roadmap with the entry into the field of food allergy with Palforzia®, the expansion of its geographic footprint and the launch of products and services in new regions. The addition of Palforzia®, the only approved oral immunotherapy treatment for peanut allergy, to Stallergenes Greer's portfolio marks an important milestone for the Group which is the only player present in both food and respiratory allergy. It is also testimony to Stallergenes Greer's long-term commitment to providing patients with effective treatment solutions for an ever-expanding range of allergic conditions.

These achievements were made possible by the focus and dedication of Stallergenes Greer's employees. On behalf of the Board of Directors, I would like to express my gratitude to all the Group's employees who, under the leadership of Michele Antonelli, have contributed to building a resilient and innovative Stallergenes Greer.

With solid fundamentals, robust and agile operations, and a relentless drive for innovation, Stallergenes Greer is well-equipped to continue shaping the future of allergen immunotherapy for the benefit of patients and the medical community.



Michele Antonelli

Chief Executive Officer

How did Stallergenes Greer perform in 2023 and what were the main challenges and highlights of the year?

2023 was an exciting and busy year for Stallergenes Greer, marked by significant advancements in all areas.

We posted robust commercial performance across all geographies: our North American operations showed consistent growth of core activities; the Europe and International region expanded its geographic footprint while successfully launching Orylmyte®; and France increased its market share and captured 30% of new prescriptions for Orylmyte®, barely a year after launch.

Another major highlight of the year was the agreement with Nestlé regarding Palforzia®. With the addition of Palforzia® to our portfolio, Stallergenes Greer now provides a clinically proven oral immunotherapy treatment for peanut allergy. This step forward in the food allergy space holds promise for people suffering from food allergy.

The year was also one of progress in the clinical field, in both respiratory and food allergies. Our European Phase III YOBİ study (Young Patients and Birch Allergy), to analyse the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis with or without asthma, is moving forward as planned.

In China, important strides were made with the completion of our clinical design study for Actair® and the submission of our investigational new drug dossier to the National Medical Products Administration. And, the Phase III Poseidon (Peanut Oral Immunotherapy Study of Early Intervention) study results, which evaluated the efficacy and safety of Palforzia® in peanut-allergic children aged 1 to 3 years, were published.

I am proud of our performance and of the engagement of our people who contributed to make 2023 another year of success.

I am proud of our performance and of the engagement of our people who contributed to make 2023 another year of success.”

The Group is now present in food allergy. What are your ambitions in this field?

We made our first step in food allergy with the addition of Palforzia® to our portfolio and firmly intend to further invest in this field. Often, when a person is tested for peanut allergy, the first recommendation of physicians is peanut avoidance. Although a peanut avoidant diet is necessary, it is not a therapeutic treatment! The lives of people with peanut allergy remain at risk of anaphylaxis in the event of accidental exposure.

Our ambition is to make more treatments available, treatments which mitigate adverse reactions and complement avoidance measures. With our entry in the food allergy space, we are further developing our competencies and leveraging our scientific network to tackle other food allergens, such as nuts as well as other foods, which represent a true burden on society.

In large markets such as China, Europe, Japan and the U.S., parents and children are faced with an unmet medical need and are hoping for solutions to treat food allergy. We can also expect that treating these allergies will not only improve the quality of life of people affected by them, but also have a significant impact on the costs associated with the burden of disease for society.


The state of research has evolved significantly over the past decade, what are the main trends to further improve the quality of life of people with allergies?

Research in the allergy field is evolving at a rapid pace. One of the trends we are seeing is the development of monoclonal antibodies which block the inflammation cascade responsible for allergy symptoms. Patients who discontinue monoclonal antibody therapy may, however, experience a relapse. And, observation of these antibodies shows that when treatment is stopped, allergy symptoms are exacerbated, which unfortunately means that the disease is not treated. Current research is investigating the combination of monoclonal antibodies with allergen immunotherapy, which could potentially improve treatment outcomes.

In my view, another significant opportunity lies in deepening our understanding of the role of allergens in the pathophysiology of allergies and their resolution. We must understand which allergens trigger the immune system response for effective treatment, as well as those that may cause adverse reactions. Clinical assessments of allergen groups are essential to inform the development of new treatment options.

Precision medicine must also be leveraged to treat allergies. By precisely targeting molecules and understanding the clinical impact of treatment, we can help physicians treat each patient more precisely.

Each patient is different, with his or her individual profile, and treatment should be adapted to each profile and specific need. This is an area in which Stallergenes Greer has solid competencies, and one in which the Group benefits from a wealth of data to adapt treatment effectively.



Moving forward, we will continue to invest our efforts in food allergy and in the generation of new data to further develop and manage the lifecycle of our therapeutic offer with new solutions.”

In the future, how will Stallergenes Greer maintain its growth momentum and continue contributing to society?

Moving forward, we will continue to invest our efforts in food allergy and in the generation of new data to further develop and manage the lifecycle of our therapeutic offer with new solutions.

For example, we have a product which we will continue to grow, more specifically in the paediatric space, thanks to dosage flexibility and the use of our connected delivery system which aims to enhance treatment adherence and compliance.

As a responsible corporate citizen and a world leader in allergen immunotherapy, it is our duty to contribute to sustaining the environment for future generations.

We are committed to lessening our impact by producing and distributing drugs with a minimal effect on the environment in terms of waste, energy consumption, pollution, and greenhouse gas emissions. And, through the Stallergenes Greer Foundation, which awarded its first Science Awards for Allergy in May 2024, we notably engage in climate action and environmental protection to progress the prevention and treatment of allergies.

About us



Stallergenes Greer boasts a broad global footprint and extensive allergen and finished AT product manufacturing capabilities.



**SAN DIEGO
CALIFORNIA
U.S.**
bulk allergens
and custom-order
products

What's new

**IPUMP® CONNECTED ALLERGY MANAGEMENT
ASSISTANT LAUNCH IN FRANCE**

AROUND
1.3M
PATIENTS TREATED WORLDWIDE¹

CHINA INVESTIGATIONAL NEW DRUG DOSSIER SUBMISSION

3 formulations

Four circular images arranged horizontally. The first shows a woman's profile with a microscope and test tubes. The second shows a man's face with a lush green forest background. The third shows a person in a blue lab coat and mask, with a background of people in a clinical setting. The fourth shows a man in a suit and tie, with a background of a handshake and various medical and business icons.

A man with a beard is carrying a young girl on his shoulders. They are both laughing and smiling. The background is a field with tall grass and a sunset sky.

Stallergenes Greer Foundation

The foundation's mission is "to create healthier futures for all" by: focusing on scientific research to bolster innovation and precision medicine; supporting academic initiatives to develop future generations of allergy healthcare professionals; and engaging in climate action and environmental protection to progress the prevention and treatment of allergies.

Our purpose

Enabling precision medicine to improve life for people with allergies.

Our ambition

Becoming the world’s leading allergen immunotherapy company.

Our strategy

Our strategy is designed to achieve our ambition of being the world’s leading allergen immunotherapy company for the long-term and deliver sustainable value to all our stakeholders: patients, the medical community, healthcare systems, colleagues, and our shareholder.

To achieve our ambition, our strategy is based on four pillars.

Excellence in execution

Our ambition is to serve patients with high quality products and optimal solutions to treat allergies thanks to a robust supply chain and state-of-the-art pharmaceutical technologies.

Strengthening our business

We aim to expand our geographical footprint and we invest in areas where we can make a difference in the lives of people with allergies. We aim to offer physicians the broadest portfolio of allergens and delivery systems to foster precision medicine and deliver successful patient outcomes.


Developing new solutions for our patients

For the benefit of patients across the globe, our objective is to further enrich the evidence of our treatments with new clinical and real-world data, improve treatment adherence with novel delivery tools, and discover and develop innovative products to treat respiratory, food and venom allergies.

Attracting and developing talents

Our people are our greatest asset: they design, develop, and deliver solutions which are tailored to the individual needs and profile of patients. We invest in the development of our colleagues who are committed to improving the quality of life of allergy sufferers.

Our business model: creating value



Governance

Stallergenes Greer is governed by a Board of Directors which determines the strategic direction of the Group.

The Executive Committee, chaired by the Chief Executive Officer, is comprised of senior leaders who represent a breadth and depth of knowledge and experience to lead our business. Together, they form a forward-thinking, collaborative, multicultural group of leaders that drive our culture of success and support our growth worldwide.

Executive Committee



From left to right: Amer Jaber, *Chief Innovation Officer* | Valérie Benhamou, *General Counsel* | Petr Tor, *Chief Commercial Officer* | Julien Storaï, *Senior Vice President, Pharmaceutical Operations* | Michele Antonelli, *Chief Executive Officer* | Tibor Nemes, *Executive Vice President, Head of Americas* | Nicola Lamacchia, *Chief Financial Officer* | Dominique Pezziardi, *President of Stallergenes SAS, Head of Western and Southern Europe* | Jérôme Tilly, *Senior Vice President, Human Resources* | Elena Rizova, *Chief Medical Officer*

Shareholding

Stallergenes Greer is a private company owned by interests associated with the Bertarelli family, which are advised by the B-FLEXION group. B-FLEXION is a private, entrepreneurial investment firm, delivering exceptional value over the generations, while also contributing positively to society.

B-FLEXION continues to drive expansion by growing operating businesses in transformative industries. In keeping with – and building upon – its heritage, these are principally in the fields of life sciences, healthcare services and digital health.

Chaired by Ernesto Bertarelli, B-FLEXION has offices across Europe and in the United States.



At Stallergenes Greer ethical business practice is part of who we are. Our Code of Ethics and Business Conduct outlines our rules of conduct, the standards to which we adhere and our responsibility towards our stakeholders. Acting with integrity and transparency, complying with the law, respecting the individual rights of colleagues and business partners guide the professional conduct of each employee, regardless of their position in the Group. Respecting these standards is a condition of belonging to Stallergenes Greer.”

PAULINE KLEIN
Compliance Manager, Europe & International

People & culture

Safety, health and wellbeing

For Stallergenes Greer, the health, safety and wellbeing of our people is a constant concern. We believe that quality working conditions are key to providing patients with the therapeutic solutions they need. In compliance with local laws and regulations, all our sites implement action plans and preventive measures applicable to both employees and onsite contractors.

Stallergenes Greer's Occupational Health and Safety Charter guarantees a safe and healthy work environment for all its employees and guides our practices. We continually seek to strengthen safety measures at our various sites. Employees working in production and laboratories receive regular training on specific safety aspects relating to their area of work.

In 2023, in France we notably set up a network of safety contact persons that goes beyond legal requirements: the appropriate scaling of the safety teams for each site ensures that available resources can be deployed effectively to guarantee an optimum level of safety, while reinforcing our safety culture.

Corporate responsibility facts

52% OF WOMEN IN EXECUTIVE POSITIONS

3.15 2023 LOST TIME INJURY FREQUENCY RATE



Giulia Belloni, International Human Resources Director, Europe and International

Diversity, equity, and inclusion

Individual differences make us stronger, and Stallergenes Greer is committed to fostering a culture where people are celebrated for who they are regardless of ability, ethnicity, race, religion, culture, gender, gender identity, sexual orientation and age. We aim to create a work environment where each person is respected and empowered to fulfil their potential.

Our Diversity, Equity and Inclusion charter is currently under development. The guidelines, applicable to all Group employees, will notably focus on key areas in which we strive for excellence: equal opportunity, gender equality, pay equity, workforce diversity. For example, in France we reaffirmed our support of employees with disabilities by granting an additional two paid leave days per year to anyone recognised as a disabled worker.

Talent development and engagement

At Stallergenes Greer, we prize our employees who come to work each day to make a difference in the lives of people with allergies. We aim to develop and retain our employees by adopting inclusive working practices and investing in their professional growth. In 2023, we finalised the development of a tool called "My talent" which aims to support and accelerate our Group-wide talent management policy.

A range of bespoke training modules, whether skill or role-based, have been developed to support employees on their continuous learning journey. These modules include Lean Six Sigma continuous improvement training and a five-week training programme at Insead called "Developing Emerging Leaders".

We value the feedback of our employees and engage in annual performance reviews to ensure their needs are heard and their performances rewarded. A Group-wide survey will also be launched in 2024 to measure employee engagement and determine areas for improvement.



To ensure the authenticity and relevance of Stallergenes Greer's values and foster engagement, a multi-disciplinary working group, comprising employees from a variety of geographies, was set up to define the values in 2024.

Community service

Giving back to the communities in which we live and work is part of our DNA. In the U.S., in 2023 Stallergenes Greer lent a helping hand to 23 charitable organisations in our local communities.

Employees participated in various events including the donation of new shoes to underprivileged children, purchasing Christmas gifts for the underprivileged children on our Angel Tree, as well as various work projects at physical organisation sites such as painting, light construction, yard work, etc. Our employees always show up in a big way to help meet the needs of our communities.

Serving the communities where we work and live is another way our employees make a difference in the lives of others. Service is a core value of the Stallergenes Greer culture."

TAMMY JOHNSON
Senior Director, Human Resources, Americas

Business environment

Approximately 30% of the global population is affected by one or more allergic conditions¹, and it is expected that by 2050, several billion people will suffer from allergies². The prevalence of allergic diseases has risen steadily over the past 60 years in both developed and developing countries³.

GLOBAL FOOD ALLERGY MARKET (BY 2030)⁴

US\$59.5bn

GLOBAL ALLERGIC RHINITIS MARKET (BY 2030)⁵

US\$20.6bn

GLOBAL AIT MARKET (IN 2030)⁶

US\$4.9bn

FOOD AND VENOM ALLERGIES: MOST COMMON TRIGGER OF SEVERE ALLERGIES



Epidemiological studies show that climate change and pollution are affecting respiratory health as evidenced by the upsurge of allergic diseases such as allergic rhinitis and asthma. Air pollution and global warming can increase the prevalence of allergic conditions and increase the severity of symptoms, notably for specific species of pollens such as ragweed. The quality of the air we breathe is a major public health concern.”

LAURENCE GIRARD

Head of Public Affairs, Pricing and Market Access

Allergies: an economic burden

The rising prevalence of allergies has a significant financial impact on healthcare systems. In the U.S. allergies are the sixth cause of chronic illness, with more than 50 million Americans experiencing allergies each year⁷. In Europe, more than 150 million people live with an allergic condition⁸. In the European Union alone avoidable indirect costs for patients insufficiently treated for allergy range between €55 and €151 billion p.a. due to absenteeism and presenteeism⁹.

Respiratory allergy

Allergic rhinitis affects between 10-30% of the population worldwide³ and symptoms have a significant impact on quality of life. A less well-known, and often underestimated, consequence is that allergies put people at a greater risk of developing asthma. People with allergic rhinitis are three times more likely to develop asthma than other people, and the risk for patients with house dust mite-induced allergic rhinitis is about six times higher than for those whose allergic rhinitis is caused by grass pollen¹⁰.

Food allergy

Food allergy affects approximately 2.5% of the general population but the spread of prevalence data is wide, ranging from 1% to 10%¹¹. Peanut allergy is one of the major causes of severe life-threatening allergic reactions. The prevalence of food allergy is increasing each decade by 1.2% worldwide, mostly driven by environmental factors (e.g. pollution, urbanisation, hygiene hypothesis, etc.) and dietary factors associated with cultural/social behaviors (e.g., obesity, vitamin D deficiency, dietary fat, etc.)¹². The only food oral immunotherapy treatment currently available addresses peanut allergy.

Insect venom allergy

Systemic-allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children¹³. Hymenoptera (honeybee, vespid, or ant) venom allergy is the most common trigger of severe anaphylaxis in adults¹⁴. As with respiratory allergy, climate change is also increasing the prevalence of venom allergy as the presence of stinging insects (such as Polistes) is expanding from Southern to Northern regions¹⁵.

AIT: a modest proposal rate

The AIT market is underdeveloped, representing approximately €1bn¹⁶. Market growth should result from increased awareness and prevalence of respiratory allergies, improved access to allergists, as well as a growing middle class in developing countries that will gain access to medical treatments. As more patients seek treatment for their allergies, the industry is gaining greater attention from the healthcare community. New technologies, such as monoclonal antibodies combined with AIT are opening new horizons to treat patients with severe allergies.

CORPORATE RESPONSIBILITY FACTS SUPPORTING RESEARCH IN ENVIRONMENTAL HEALTH

Through the Stallergenes Greer Foundation, we sponsor research efforts in the field of respiratory airway diseases. We encourage pioneering advances that integrate climate action and environmental protection into research on the prevention and management of allergic diseases via the foundation’s Environmental Health Award.

1. World Allergy Organization, Immunology and Biologics Symposium 2013. <https://worldallergy.org/symposium2013>. 2. J. Lotvall et al. (2012). “We call for iCAALL: International Collaboration in Asthma, Allergy and Immunology.” The Journal of allergy and clinical immunology 129(4): 904-905. 3. WAO White Book on Allergy: Update 2013. R. Pawankar, G. W. Canonica, S. Holgate and R. Lockey. Publisher: World Allergy Organization 2013. 4. Zion Market research. 5. Coherent Market Insight. Online: <https://www.coherentmarketinsights.com/market-insight/allergic-rhinitis-drugs-market-1201>. 6. Market Research Future. Global Allergy Immunotherapy Market Overview. Online: <https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market-1517>.

7. Centers for Disease Control and Prevention. Highly Allergic Travelers. CDC Yellow Book 2024 8. European Federation of Asthma and Allergy Associations (EFA). Allergy. Online: <https://www.efanet.org/inform/patient-evidence/allergy>. 9. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review T. Zuberbier, J. Lötvall, S. Simoons, S. V. Subramanian, M. K. Church. 10. Bergeron C, Hamid Q. Relationship between Asthma and Rhinitis: Epidemiologic, Pathophysiologic, and Therapeutic Aspects. Allergy Asthma Clin Immunol. 2005 Jun 15;1(2):81-7. doi: 10.1186/1710-1492-1-2-81. Epub 2005 Jun 15. PMID: 20529228; PMCID: PMC2877070. 11. World Allergy Organization. 12. Dunlop & Keet, 2018, and Peters et al., 2022. 13. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. 2017 <https://onlinelibrary.wiley.com/doi/10.1111/all.13262><https://doi.org/10.1111/all.13262> 14. Worm M, Moneret-Vautrin A, Scherer K, et al. First European data from the network of severe allergic reactions (NORA). Allergy. 2014;69(10):1397–1404. 15. Impact of climate change on insect-human interactions. Arantza Vega, Leopoldo Castro. 16. Market size (€1bn) and expected growth (2%): global data and internal estimates share of AIT market in the global allergic rhinitis market (12%): Visiongain report 2018.

About allergens and allergen immunotherapy

Allergy is a disorder of the immune system which reacts to a normally harmless foreign substance such as house dust mites, pollens, or certain foods. In people with allergies, the immune system produces antibodies that identify a particular allergen as harmful following contact, ingestion or even inhalation. The immune system’s reaction can cause inflammation of the eyes, skin, sinuses, respiratory airways, digestive system and may lead to anaphylaxis.

Allergy diagnosis

The diagnosis of respiratory allergies is based on clinical history, physical examination, allergy tests and specific questions. Two diagnostic methods are available to identify the triggering allergens in individuals: prick tests and blood tests. For food allergy, an additional test called an oral food challenge may be performed.

- Prick tests: via a prick to the skin, the individual is exposed to the suspected allergen and monitored. After approximately 20 minutes, the skin is observed for any signs of reaction to one or several of the allergens: redness, swelling, itching.
- Blood tests: allergen blood tests detect allergen-specific antibodies in the blood. Blood test results are available in a few days.
- Oral food challenge¹: for food allergies, to help confirm the

diagnosis, medical practitioners may perform an oral food challenge. During the oral food challenge, which takes place in a medical setting under medical supervision, the patient is fed gradually increasing amounts of the suspected food in timed intervals. During the feeding, there is a risk of an allergic reaction, which can be severe. Should an allergic reaction occur, the reaction is managed by medical personnel, the allergy is confirmed, and correct advice for management is provided.

Allergen immunotherapy

Allergen immunotherapy (AIT) is an allergy treatment designed to treat the underlying cause of the disease as well as have a long-lasting effect on all symptoms by inducing tolerance in the immune system².

After an accurate diagnosis of the type of allergy and responsible allergens, patients, in line with their healthcare practitioner’s prescription, receive a targeted treatment. Through the repeated administration of specific allergens to patients, the immune

system builds resistance by changing the types and proportions of antibodies (immunoglobulins) and proteins (interleukins) it produces when it is exposed to the allergen. Because it treats the root cause, AIT results in immunologic tolerance, i.e. a decrease in the body’s reaction to an allergen.

An AIT treatment for respiratory or insect venom allergies can take a minimum of three years³ to achieve disease modification.

AIT is the only causative treatment with the goal of inducing allergen tolerance in individuals with venom or respiratory allergies⁴.


For food allergy, oral immunotherapy (OIT) aims to raise the threshold that may trigger an allergic reaction and protect against accidental exposure of the allergen⁵.

Food avoidance is the only way to prevent an allergic reaction but achieving full avoidance is very difficult. OIT has emerged as an alternative for the desensitisation of patients with food allergy and offers true hope by mitigating the risk of accidental exposure. Food allergen immunotherapy is carried out in a medical setting. People with food allergies should carry an epinephrine auto-injector.

The most difficult aspect of food allergy for patients and their parents is a feeling of helplessness related to not having control over accidental exposures to their allergens. Most peanut allergic patients don’t want to eat peanut, but the issue is around social events, such as going to a sleepover or birthday party, being scared by a cupcake or a birthday cake, or Halloween treats.”

MELANIE M. MAKHIJA,
MD, Attending Physician, Allergy and Immunology and Associate Professor of Paediatrics (Allergy and Immunology), Northwestern University Feinberg School of Medicine (Chicago, Illinois).

1. Food Allergy Canada. Food allergy basics, Food allergy 101, Diagnosis. Online www.foodallergycanada.ca. Last accessed March 2024. 2. Global Atlas of Allergy, EAACI 2014. 3. Penagos M, Durham S. Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy. Allergy Asthma Proc 2022 43(4):292-298. 4. AIT: New Avenues in Allergen Immunotherapy. www.foodallergycanada.ca. Wolfgang Pfützner, Christian Möbs. 5. AAAAI. The current state of oral immunotherapy. Online: <https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/the-current-state-of-oral-immunotherapy>.




Respiratory allergy

Among respiratory allergies, allergic rhinitis is the most common disease affecting between 10% and 30% of all adults and as many as 40% of children¹. Allergic rhinitis is also frequently associated with asthma, which is found in 15% to 38% of patients with allergic rhinitis and nasal symptoms are present in 6% to 85% patients with asthma². The most common aeroallergens include house dust mites, pollen (trees, grass, weeds), mould and pet dander.




Food allergy

Food allergy affects approximately 2.5% of the general population but the spread of prevalence data is wide, ranging from 1% to 10%³. The most common foods that cause allergic reactions, whether eaten separately or as an ingredient, even in trace amounts, are milk, egg, fish, shellfish, tree nuts, peanut, wheat, and soy bean⁴.



Insect venom allergy

In adults, close to 50% of severe anaphylaxis cases are caused by insect stings, against a little over 20% in children⁵. The most common insects causing severe allergic reactions include honeybees (*Apis mellifera*), social wasps including yellow jackets (*Vespula* and *Dolichovespula*), paper wasps (*Polistes*), hornets (*Vespa*), and stinging ants (*Solenopsis*, *Myrmecia*, *Pachycondyla*, and *Pogonomyrmex*), and bumblebees (*Bombus*)⁶.



Veterinary allergies

Cats, dogs and horses can have allergic reactions to a variety of environmental substances or allergens. Allergies develop when a pet's immune system overreacts to something in their environment, something they eat, or something that stings or bites them. Most allergies in animals fall into three categories: environmental allergies, food allergies, and insect sting allergies.

1. WAO White Book on Allergy: Update 2013. R. Pawankar, G.W. Canonica, S. Holgate and R. Lockey. Publisher: World Allergy Organization 2013. 2. Brozek et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016, revision J Allergy Clin Immunol 2017 Vol. 140 Issue 4 Pages 950-958. 3. Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol 2024;153:576-94. 4. FDA. Food allergies. Online: <https://www.fda.gov/food/food-labeling-nutrition/food-allergies>. Last accessed March 2024. 5. Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M, Cardona V, et al. First European data from the network of severe allergic reactions (NORA). Allergy (2014) 69(10):1397-404. doi: 10.1111/all.12475. 6. World Allergy Organ J. 2019 Oct; 12(10): 100067. Worldwide perspectives on venom allergy. Peter Korošec, Thilo Jakob, Harri Harb, Robert Heddl, Sarah Karabus, Ricardo de Lima Zollner, Julij Selb, Bernard Yu-Hor Thong, Fares Zaitoun, David B.K. Golden, and Michael Levin.

Serving patients with allergies





Respiratory allergy patient journey




Respiratory allergies follow a chronic and progressing disease course, especially when left untreated¹. Allergic rhinitis is often both underdiagnosed and undertreated, and a patient may have waited six years after the onset of symptoms to see a specialist².

A complex journey



- Psychological symptoms: fatigue, irritability, poor sleep, negative effect on concentration and performance
- Allergic conjunctivitis with itchy, red and watery eyes
- Allergic asthma with dry cough and shortness of breath
- Skin or digestive discomfort
- Wheezing
- Constricted airways in the lungs
- Sneezing and blocked or runny nose
- Swelling and itching in the oral area



Quentin Bourgoïn, Deputy Head of Analytical Team, France

Patients may have waited 6 years after the onset of symptoms to see a specialist².

Globally, over 400 million people⁵ suffer from allergic rhinitis.

Asthma and allergic rhinitis are estimated to result in more than 100 million⁶ lost workdays and missed school days every year in Europe.

Allergen immunotherapy is used in less than 10% of eligible patients⁷ globally.



1. Bousquet J, et al. Allergy 2008;63(S86):8-160 - Canonica GW, et al. World Allergy Organ J 2008;1:138-44 - Valovirta E. (2011) EFA Book on Respiratory Allergies - Raise Awareness, Relieve the Burden. www.efanet.org. Last accessed March 2024. 2. Baena-Cagnani et al. World Allergy Organization Journal (2015) 8:10 DOI 10.1186/s40413-015-0057-0. 3. Tan R, Cvetkovski B, Kritikos V, Price D, Yan K, Smith P, et al. Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon. Asthma Res Pract. 2017;3:8. 4. Peter Hellings et al. Rhinology 2020, and Professor Glenis Scadding et al., WAO Journal 2020. 5. Pawankar R, Canonica GW, ST Holgate ST, Lockett RF, Blaiss M: The WAO White Book on Allergy (Update. 2013). 6. The European Academy of Allergy and Clinical Immunology Advocacy Manifesto: <https://emj.emghealth.com/wp-content/uploads/sites/2/2019/12/Connecting-the-Dots-Between-Skin-and-Allergy.pdf>. Last accessed March 2024. 7. Jutel M, et al. J Allergy Clin Immunol 2015;136:556-68.

Food allergy patient journey



Food allergy symptoms are most common in babies and children but can appear at any age, and people can develop an allergy to foods they have eaten for years without any allergic reaction¹. Symptoms can appear a few minutes after ingesting a food and up to two hours later². Food allergy reactions include a variety of clinical conditions affecting the gastrointestinal tract, skin and lungs, as well as sometimes fatal anaphylaxis³. Food allergy diagnosis is difficult and about 50-60% percent of all blood tests and skin prick tests will yield a “false positive” result⁴.

A distressing journey



200–250 million people worldwide are affected by food allergy⁵.

Food allergy is likely to affect approximately 1 in 10 adults⁶, and 1 in 12 children⁷ in the U.S.

1. ACAAI. Food allergy. Online: <https://acaai.org/allergies/allergic-conditions/food/>. Last accessed March 2024. 2. Food Allergy Research and Education (FARE). Online: <https://www.foodallergy.org/resources/common-questions>. Last accessed March 2024. 3. Nature Review, Disease Primers. Food allergies. Harald Renz et al. Online: https://www.immunetolerance.org/sites/default/files/Renz_Nat%20Rev%20Dis%20Primers_2018.pdf. Last accessed March 2024. 4. Food Allergy Research and Education (FARE). Blood tests. Online: <https://www.foodallergy.org/resources/blood-tests>. Last accessed March 2024. 5. European Commission. Cordis. Point-of-care device based on KETs for diagnosis of food allergies: <https://cordis.europa.eu/project/id/768641/fr>. Last accessed March 2024. 6. Gupta RS, Warren CM, Smith BM, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open. 2019;2(1):e185630. 7. Gupta RS, Warren CM, Smith BM, et al. The public health impact of parent reported childhood food allergies in the United States. Pediatrics. 2018;142(6):e20181235.



Jaime

Therapeutic Area Medical Lead
New Pipeline and Expansion

Science

“

***Precision medicine** is the focus of our research. By analysing information about an individual's characteristics and characterising their immune response, we strive to provide a more personalised approach to the diagnosis and treatment of allergic disease. At Stallergenes Greer, we aim to identify clinical and serological biomarkers that allow us to predict and monitor the efficacy of our allergen immunotherapy (AIT) treatments. As an example, our research supports the interest in IgG2 (immunoglobulin G2, antibodies produced by the immune system during AIT treatment) as an emerging biomarker related to high responders to AIT.”*

JAIME SANCHEZ LOPEZ

CORPORATE RESPONSIBILITY FACTS REAL-WORLD DATA TO INCLUDE THE PATIENT'S PERSPECTIVE IN AIT IMPACT EVALUATION

Real-world data helps gain a better understanding of AIT treatment in real life while enhancing medical knowledge. The Group's PRACTIS observational prospective study has been finalised with the evaluation of the Patient Benefit index in over 700 patients. This real-world study was designed to show how SLIT met patient expectations when treated for allergic asthma, or allergic conjunctivitis regardless their age and the causal allergen.

Safety, efficacy and effectiveness data on Stallergenes Greer's AIT products have been collected across the Asia Pacific region, Canada, Europe, the Middle East, the U.S., Russia, and Switzerland.

More than
10,500¹
patients included in the Group's double-blind placebo-controlled studies over 30 years

More than
130,000¹
patients treated with the Group's AIT products in real-world studies over 30 years

1. Internal source.

Investing in data generation

To support the effectiveness of our AIT portfolio, Stallergenes Greer continues to invest in clinical and real-world data generation.

Two randomised clinical studies are underway. YOBİ (Young Patients and Birch Allergy) to assess the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis with or without asthma. More than 550 patients across 12 countries were successfully recruited for the study. And in Russia, the Staloral® Mugwort study to evaluate the impact of Staloral® versus placebo on the Average Adjusted Symptom Score for the treatment of patients with mugwort pollen-induced seasonal rhinitis with or without allergic conjunctivitis and/or asthma.

The EfficAPSI real-world study, which includes 430,000 patients in France, to evaluate the therapeutic benefits of sublingual liquid AIT treatment on the onset and worsening of asthma in patients with allergic rhinitis with or without asthma has been finalised and study results will be published in 2024. In Germany, PASS, a post authorisation observational study on the safety of Orylmyte®, the Group's AIT tablet for house dust mite allergy, is ongoing. Results are expected by the end of 2024.

Leveraging open innovation

In 2023, we continued to foster research collaborations to identify candidate biomarkers of AIT efficacy with the support of world-class organisations including Imperial College London (U.K.), the Swiss Institute of Allergy and Asthma Research (Davos, Switzerland) and Monash University and Alfred Hospital (Melbourne, Australia).

These collaborations will deepen knowledge of the physiopathology of allergic diseases and immune responses (onset of action, memory responses) triggered by AIT which could have implications on the routine practice of allergology.

Stallergenes Greer has also started to explore new therapeutic approaches based on bitherapies combining biologics and AIT solutions with the aim of improving clinical benefits in individuals with allergic asthma.

I had already been stung by a wasp and didn't experience any symptoms. The second time, I was gasping, dizzy and my chest was tight. Thankfully, I made it to emergency care in time and was subsequently diagnosed with wasp venom allergy."



Julian
Allergic to venom



Hafida

Production Director

Technical operations

“Biologic drugs are derived from living cells and their development requires a high level of expertise. Because the physical and chemical properties of biopharmaceutical material can affect the quality and stability attributes of a product, characterisation is critical throughout development and manufacturing. To ensure the quality and purity of our treatments, we use leading edge technologies, carry out stringent controls and apply hundreds of process controls to ensure that quality attributes are delivered.”

HAFIDA ELMIR


Stallergenes Greer is ramping up its Technical Operations to meet the evolving needs of the pharmaceutical industry, anticipate future demand and continuously ensure the efficient delivery of its allergen immunotherapy treatments to patients.

Supply chain resilience

Securing our supply chain remains a strategic imperative for the Group. We continuously strengthen the visibility, reliability, flexibility and efficiency of our supply chain to ensure uninterrupted product availability for the people who depend on them. Thanks to planning and visibility, our teams can anticipate fluctuations and manage our production capacity to ensure that our treatments remain available.

CORPORATE RESPONSIBILITY FACTS ECO-DESIGNED PACKAGING

Our new fully automated, connected and flexible packaging line in Antony (France) is capable of producing packaging with a significant level of personalisation, at high speed. It easily adjusts to local pharmaceutical regulations while ensuring both the reliability of our packaging processes and the ability to meet future demand. It can evolve over time in line with the Group's projects, such as providing the possibility to eco-design packaging, which is one of the Stallergenes Greer's strategic commitments in terms of corporate responsibility.



UPSTREAM

Production of source material

Internal/external sourcing

Extraction

Source material

extraction/filtration

Excipient

Active pharmaceutical ingredient (API)

Bulk

Adjustment / mixing / dilution

Pre-filled vials or tablets

**DOWNSTREAM/
PACKAGING**

SHIPMENT

**Innovation
in motion**

Each year, Stallergenes Greer invests significant amounts in its industrial tool to adapt to the latest regulatory standards and meet increasing market demand for the Group's AIT treatments.

In line with this strategy, in 2023, the Group internalised the production of its AIT tablets at its Antony (France) site to anticipate demand; the first batches have already been released for France. A new flexible aseptic filling line is also being implemented in Antony and will be operational in 2025.

**Operational
efficiency to deliver
value for our
patients**

Because our AIT treatments cater to the specific needs of patients, we continuously train our people in areas such as quality assurance, quality control, product development, and regulatory, and ensure they obtain certifications in key areas.

Stallergenes Greer is committed to safeguarding, and building on, its legacy expertise in AIT while constantly upgrading its industrial practices and processes to prepare the future.

“

My birch allergy symptoms were so severe that I frequently missed school. And when spring came, while my friends were outdoors, I couldn't wait for the rain to fall!”

Calista
Allergic to birch pollen

Operating review



For the Europe & International region, 2023 was a year of expansion marked by the launch of products in new countries and the entry in the food allergy space. Despite a challenging economic environment, the region maintained its market positions and experienced growth.

Germany, a dynamic market

The German market, which is the largest allergen immunotherapy (AIT) market worldwide, continues to structurally transform because of the Therapy Allergen Ordinance (TAO) process which ensures that only registered and clinically proven allergen treatments remain on the market. Stallergenes Greer is one of the players to offer a fully registered evidence-based AIT portfolio for key allergens.

Stallergenes Greer continued to be the fastest growing company in terms of sales values¹. This performance was achieved thanks to investments made over the past years in sales force expansion to increase our share of voice, as well as in scientific educational events to cover a larger target audience.

¹. Based on internal estimates

Expanding our product portfolio and geographic footprint

Stallergenes Greer continued to expand its geographic presence in the Nordics region (Denmark, Finland, Sweden and Norway). The Group's recently registered house dust mite and grass pollen AIT tablets Aitmyte® and Aitgrys®, received price and reimbursement approvals where submitted and will be commercialised in 2024 with the support of Stallergenes Greer's teams.

The year was also marked by the launch of Actair®/Orylmyte® in Italy, the Netherlands, Poland, Qatar, and Spain. The Italian and Spanish markets are undergoing change brought about by “regularisation” processes which, similarly to the TAO in Germany, could lead to the market exit of non-registered AIT treatments.

The Group also made important strides in the United Kingdom with the availability of its peanut allergy oral immunotherapy (OIT), Palforzia®, the submission for registration of Oralair® with the Medicines and Healthcare Products Regulatory Agency, and the registration of Actair® in 2022.

A new commercial approach, undertaken in Japan by the Group's partner for house dust mite AIT treatment, is bearing fruit with a rise in new patient initiation and first signs of market share gains.

Europe & International

Delivering on our expansion strategy

Treating patients with peanut allergy

With the addition of Palforzia®, the only available oral immunotherapy treatment for patients with peanut allergy, to the portfolio, Stallergenes Greer became the first company to be present both in respiratory and food allergies.

In Europe, Palforzia® is already on the market in Austria, Germany, the United Kingdom, and Switzerland. The Europe and International teams are currently preparing the launch of Palforzia®, which will depend on price and reimbursement processes, in additional European countries.

In the future, Stallergenes Greer is committed to making Palforzia® available to an increasing number of patients. The recent findings of the Poseidon (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) Phase III study highlight the clinical significance and favourable safety profile of Palforzia® for peanut-allergic children aged 1 to 3 years. The extension of indication to this age group is under assessment by health authorities.

Driving organisational growth

To better navigate the changing market landscape, the region has implemented a series of training programmes to support the development of its teams. Training on critical competencies, for both sales managers and executives, are being rolled out throughout the region to improve performance and optimise processes and resources.

By focusing on commercial excellence and developing and engaging its teams, Stallergenes Greer aims to better cater to the needs of patients and healthcare professionals.

“House dust mite allergy is challenging! Eviction of house dust mites is complicated as they can be found throughout a home on bedding, pillows, carpets, but also on clothing and soft toys. House dust mite allergy can be a significant issue all year round.”

CAROLINE, MOTHER OF PRUNE AND TIMOTHÉE



Prune and Timothée
Allergic to house dust mites

A hand is holding a small, cloud-shaped wooden sign that says "CONTAINS NUTS" in a simple, sans-serif font. The sign is being held over a bowl of bread. The background is a warm, out-of-focus bokeh of light and dark spots, suggesting a kitchen or bakery setting. The overall tone is professional and informative.

North America

Strong leadership in allergen immunotherapy

In North America, Stallergenes Greer continues to be a prominent player in the allergen immunotherapy (AIT) landscape, known for our strong market presence and unwavering support from our dedicated service teams. Despite economic headwinds faced in 2023, we remained resilient, safeguarding our core business while maintaining healthy profit margins. This resilience underscores the enduring value we continue to offer to our customers.

Establishment of a dedicated Food Allergy business unit

In a significant move during the fall of 2023, Stallergenes Greer acquired the rights to the peanut oral immunotherapy Palforzia®. Subsequently, our focus has been on establishing a specialised Food Allergy business unit. This endeavor involved building dedicated sales and commercial teams and working to fully transition the product into the AIT portfolio.

Investing in our core business

Recognising the escalating demand for allergen extracts, Stallergenes Greer has made strategic investments in enhancing manufacturing efficiencies. These efforts are particularly geared towards elevating production levels for pollens, our most sought-after extract category. Our California manufacturing plant, Allermed Laboratories, LLC plays a key role in this undertaking. By bolstering our inventory of key items, we aim to differentiate ourselves in

the market, creating a distinctive identity that resonates with our target demographic and fosters brand loyalty.

Community engagement

In alignment with our commitment to advancing allergy care, Stallergenes Greer actively participated in and exhibited at prominent national allergy conferences, namely AAAAI in San Antonio, Texas, and ACAAI in Anaheim, California. These platforms provided invaluable opportunities to engage with allergy specialists, showcasing our comprehensive allergy portfolio.

Further, we demonstrated our commitment to nurturing future talent in the field of allergy by sponsoring 10 fellows-in-training (FITs) with scholarships to attend the ACAAI conference. This initiative not only supports the educational pursuits of emerging allergy specialists but also underscores our dedication to fostering leadership within the healthcare community.

As we navigate the dynamic landscape of AIT in North America, Stallergenes Greer remains steadfast in its mission to deliver innovative solutions and unparalleled support to our customers. Through strategic initiatives and community engagement efforts, we are poised to sustain our leadership position while driving positive impact in allergy care.

Sustained performance of veterinary business

The U.S. veterinary business, which celebrated its 40th anniversary of manufacturing, continues to provide veterinarians and pet owners with USDA-licensed allergen extracts and AIT to help animals suffering from allergies. In 2023, we collaborated with real owners of pets who have been through the allergy journey and were interested in telling their stories—three dog owners and two cat owners passionately talk about their experiences with their pets’ allergies and how AIT has helped their pets live more comfortable lives. These dynamic and emotion-evoking videos will be shared on the Pets Get Allergies website as well as on our social media channels to educate pet owners about AIT and how it can help their pet get the relief they need from allergies.

Additionally, we sponsored a veterinary dermatologist who developed an accredited continuing education course for primary care veterinarians to help them learn more about how to confidently and accurately diagnose and treat pets with atopic dermatitis.

Canada: an expanding portfolio

In 2023, our Canadian operations continued to invest in quality and inventory management systems and build internal expertise to support future growth that keeps patients at the center.

A veterinary biologic import license was awarded to Stallergenes Greer Canada during the year and the affiliate is now also serving veterinary dermatologist customers with bulk allergenic extracts.

Support for allergy research continued in 2023 with sponsorship of the Canadian Asthma, Allergy and Immunology Foundation (CAAIF) and the Food Allergy Immunotherapy Program (FAIT) at BC Children’s Hospital (Vancouver, British Columbia).

As a veterinary dermatologist, I receive questions every single day from primary care veterinarians who are curious about allergen testing and allergen immunotherapy. Sadly, there is so much confusion, and so many misconceptions, out there about these important topics – amongst both veterinary teams and pet owners. These often result in under-utilisation, inappropriate utilisation, and/or suboptimal outcomes with allergen testing and immunotherapy. I created this course to help clear up the confusion and misconceptions to help everybody better understand how, when, and with which patients to utilise allergen testing and allergen immunotherapy.”

Dr. Meagan Painter
DVM, DACVD, Board-Certified Veterinary Dermatologist

2023 was another eventful year for Stallergenes Greer France with the successful launches of new products and services and the consolidation of leadership positions¹, thanks to the engagement of its teams.

New products and services

The year notably marked the launches of Orylmyte®, the Group's tablet for the treatment of house dust allergy, and iPUMP®, the first connected allergy management assistant, on the French market.

Orylmyte®, the only available allergen immunotherapy (AIT) tablet for house dust mite allergy with dose escalation, acts from the first months of treatment and has demonstrated efficacy on allergic rhinitis symptoms. A year after its launch, the tablet benefits from an important presence in France with a 29% market share in terms of new patient initiation, representing one out of three patients initiating AIT in tablet form for house dust mite allergy.

iPUMP®, the Group's connected allergy management system developed with Aptar Pharma, aims to improve observance and optimise treatment outcomes for both children from 5 years of age and adults undergoing AIT treatment. More than 1,300 patients are currently using iPUMP® and Stallergenes Greer will soon launch a retrospective study to investigate its potential impact on treatment observance. Beyond this study, the perceptions of patients after six months of use, as well as the feedback and satisfaction rates of physicians, will also be assessed.

Cat allergy, an underserved need

Since its launch, Staloral® Cat 300IR/mL has posted strong and steadily increasing sales, confirming an unmet medical need in the field of allergy to cat dander.

In 2023, we trusted an opinion survey to BVA among 96 French allergy specialists to study allergy management practices for cat dander and the role of AIT. The survey highlighted the specific levers and obstacles to desensitisation for this allergy: allergy to cat dander remains underestimated by allergy specialists and is less commonly treated with AIT with a quarter of allergic patients treated compared to half of patients with house dust mite allergy. Cat dander is a highly pervasive allergen, and it is estimated that half of the people sensitised to cat dander do not own a cat.

France

Innovating in allergen immunotherapy

1. Based on internal estimates

OrdoIZZY+, personalised services for patients initiating treatment

In addition to its OrdoIZZY secure website dedicated to patients undergoing allergen immunotherapy, the French affiliate launched OrdoIZZY+, a tailored service for new patients identified by allergy specialists as requiring a personalised programme.

The service was specifically designed for patients initiating AIT for cat or house dust mite allergy. A team of dedicated customer service managers was trained to help patients optimise management of the initiation of their named patient product.

Life-threatening allergies

Stallergenes Greer France is fulfilling its commitment to optimise care for patients with bee and wasp venom allergy and obtained the price of Albey® bee venom and wasp venom specialities, which was published by the French Official Journal in 2023. This opens the way for patients with venom allergies to be cared for not only in a hospital setting but also in the office of their healthcare practitioner thanks to the availability of maintenance dosages in pharmacies, thus optimising convenience for patients during the maintenance phase of their treatment.

The upcoming launch of Albey® combined with the addition of peanut allergy oral immunotherapy Palforzia®, which will be launched on the French market in 2024, opens a new chapter for Stallergenes Greer in France with the treatment of severe allergies and an increased presence in hospitals.

“**Allergy to cat dander** is a potentially severe allergy associated with a risk of asthma. Cat dander is extremely volatile and can be found everywhere in homes, including on clothing, even when cats are not present. Since the allergen can only be eliminated by separating the patient from the pet, which is - as I can easily understand - often unthinkable, being able to offer allergen immunotherapy is a relief for doctors and patients alike when pharmacotherapies or symptomatic treatments are not sufficient.”



Delphine Delalande
MD

Impact





The Stallergenes Greer Foundation’s mission is to “Create healthier futures for all”. The foundation pursues a comprehensive approach calling for “the collaborative efforts of multiple disciplines working locally, nationally, and globally, to attain optimal health for people, animals and our environment”, as defined by the One Health initiative. Placed under the aegis of the Fondation de France, the Stallergenes Greer Foundation carries out its actions in full transparency and in respect with its ethical commitments to the Fondation de France.

Focus areas

The Stallergenes Greer Foundation focuses on three key areas.

Advancing scientific research to bolster innovation and precision medicine

By focusing on scientific innovation and research, the Stallergenes Greer Foundation aims to support the scientific community in furthering allergology research to discover and develop novel solutions for people with allergic diseases.

Supporting academic initiatives to further develop future generations of allergy healthcare professionals

Because the future of allergology is being prepared today, the Stallergenes Greer Foundation encourages and supports the emergence of innovative academic projects.

Engaging in climate action and environmental protection to progress the prevention and treatment of allergies

Because the quality of the air we breathe has significant consequences on our health and can exacerbate chronic respiratory diseases¹, the Stallergenes Greer Foundation is committed to raising awareness about climate change and environmental protection for the benefit of populations around the globe.

Stallergenes Greer Foundation

About Fondation de France

Created in 1969, Fondation de France is a private organisation recognised of public interest, whose mission is to support all forms of generosity to translate them into effective actions of general interest. With close to 1,000 hosted foundations, Fondation de France supports more than 10,000 promising and innovative initiatives in France and abroad each year. Fondation de France is independent and private and operates thanks to the generosity of donors.

1. D'Amato G, Liccardi G, D'Amato M, Cazzola M. The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy. Respir Med. 2001 Jul;95(7):606-11.

Governance

The Stallergenes Greer Foundation is governed by a Board of Trustees which brings together the Managing Board and the Scientific Board.

Managing Board

The Managing Board is composed of four Stallergenes Greer executive officers:

Michele Antonelli, Chairman of the Stallergenes Greer Foundation; **Amer Jaber**, Scientific Director Stallergenes Greer Foundation; **Catherine Kress**, Secretary General of the Stallergenes Greer Foundation; **Dominique Pezziardi**, Strategy Director of the Stallergenes Greer Foundation

Scientific Board

The Scientific Board is composed of four independent members:

Pascal Demoly, Professor of Pulmonology and Head of Department at the University Hospital of Montpellier (France); **Alessandro Fiocchi**, MD, Director of Allergy at Pediatric Hospital Bambino Gesù, Rome, Vatican City (Italy); **Carla Irani**, Associate Professor, Internal Medicine and Clinical Immunology, Allergology - Immunological Asthma at Hôtel Dieu de France University Medical Center, Beirut (Lebanon); **Kari Nadeau**, MD, PhD, Chair of the Department of Environmental Health at Harvard T.H. Chan School of Public Health, Boston (MA, U.S.A.)

Visit the Stallergenes Greer Foundation website:
www.stallergenesgreer-foundation.org

Science awards for allergy

The foundation established the Stallergenes Greer Foundation Science Awards for Allergy which recognise outstanding contributions to allergy research and environmental health initiatives and allocate up to €150,000 to support these efforts.

The winners of the 2023 edition were announced in May.

Innovation Awards

Rising Talent Category

Assoc. Prof. Jennifer Koplin, Group Leader, Childhood Allergy & Epidemiology, Child Health Resarch Centre, The University of Queensland, Australia, recognised for her research: *“Association between earlier introduction of peanut and prevalence of peanut allergy in infants in Australia”*.

Assoc. Prof. Rachel Peters, Principal Research Fellow, Murdoch Children’s Research Institute, Australia, recognised for her research: *“Multiple food allergy phenotypes in infancy are associated with lung function deficits and asthma at 6 years of age: a prospective cohort study in Australia”*.

Mid-Career Scientist Category

Assoc. Prof. Jenny Hallgren Martinsson, Senior Lecturer, Department of Medical Biochemistry and Microbiology Uppsala University, Sweden, recognised for her research: *“Circulating mast cell progenitors increase during natural birch pollen exposure in allergic asthma patients”*.

Dr Luciana Kase Tanno, Researcher, University Hospital of Montpellier, France, recognised for her research: *“Changing the history of anaphylaxis mortality statistics through the World Health Organization’s International Classification of Diseases 11”*.

Environmental Health Award

Dr Dorra Gharbi, Post doctoral research fellow, Allergology and Immunology Unit, Lung Institute University of Cape Town, South Africa, recognised for her research: *“Allergenic tree pollen in Johannesburg and Cape Town as a public health risk: Towards a sustainable implementation framework for South African cities”*.

“The mission of the Stallergenes Greer Foundation is testimony to our commitment to global health. Allergic diseases impose a considerable burden on patients, health systems and society and we believe that the foundation has a key role to play in driving innovation in the field of allergy. With the Science Awards for Allergy, the foundation, together with its grant recipients, is committed to advancing allergy research for the benefit of populations across the globe.”

CATHERINE KRESS
Secretary General of the Stallergenes Greer Foundation

Care beyond allergy

our corporate responsibility programme

Progressing on our corporate responsibility journey

2021

Maturity assessment

2022

Materiality analysis

“Care Beyond Allergy” corporate responsibility programme
20 commitments

2023

Definition of strategic key performance indicators (KPI)

Updating of corporate responsibility governance model

2024

Preparation for CSRD requirements
Double materiality assessment



SOCIETY

“Patient needs drive our innovation to fight against all kinds of allergies”



ENVIRONMENT

“We are committed to advancing climate action and preserving nature to boost the prevention and treatment of allergies”



SOCIAL

“Investing in our people and empowering them to unleash their full potential”



GOVERNANCE

“Building trust with our stakeholders every day”



Care Beyond Allergy, moving forward with determination

2023 marks an important milestone for our Care Beyond Allergy programme with the definition of 12 KPIs which provide a quantifiable, objective and transparent basis for measuring progress toward our 2030 corporate responsibility ambition, while aligning with the Group’s business goals.

In 2024, Stallergenes Greer will establish the baseline for all the Group’s KPIs to ensure that measurement processes are robust and correctly reflect our commitment to sustainability. To further solidify our environmental stewardship, we are working with external experts to define reduction trends such as those pertaining to greenhouse gas (GhG) emissions.

The integration of corporate responsibility initiatives in our Group’s objectives illustrates our commitment to sustainable business practices. Through regular updates at Stallergenes Greer’s Strategic Project Committee and thorough discussions at the Corporate Responsibility Committee, we ensure that corporate responsibility is a fundamental component of our organisational strategy.

As part of our commitment to sustainability, the Group launched a series of e-training sessions aimed at infusing a new culture throughout our organisation. In 2023, 82.5% of employees completed sustainability training. As we move forward on our corporate responsibility journey, we recognise the importance of not only measuring progress towards our corporate responsibility ambitions but also nurturing a workplace environment where every individual feels valued and empowered to contribute to our collective success.

Stallergenes Greer is proactively preparing for the future European Corporate Sustainability Reporting Directive (CSRD) requirements applicable in 2026. By staying ahead of regulatory changes, the Group is assuring its readiness to meet evolving standards and strengthening its determination to embrace comprehensive sustainability practices.



SOCIETY

Key commitments

- Accelerate research to offer a comprehensive portfolio of innovative and personalised solutions against allergies
- Contribute to gathering scientific and medical knowledge on allergies and the socioeconomic impact of allergen immunotherapy
- Ensure patient security and treatment supply
- Join efforts with patients and practitioners to enhance the quality of life of allergy sufferers and improve the patient journey

2030 ambition

- Extend access to and use of Stallergenes Greer allergen immunotherapy products
- Increase the production capacity of our new sublingual specialty production line each year
- Empower patients by integrating their voice in our initiatives



ENVIRONMENT

- Support our sites in adjusting to environmental challenges
- Use natural resources responsibly
- Contribute to the objectives of the Paris Agreement
- Implement eco-friendly packaging solutions
- Increase awareness on environmental challenges
- Support research in environmental health and ecology of health, with a specific focus on the impact of air pollution on respiratory diseases

- Ensure that volume growth until 2030 will be delivered by reaching efficiencies on water consumption
- Reduce our GhG emissions (scope 1, 2, 3) compared to baseline
- An eco-friendly pack pilot for sublingual specialty available for implementation in manufacturing by 2025



SOCIAL

- Be a safe place to work
- Be the right place to work
- Invest in training and professional development
- Upgrade our talent programme to anticipate tomorrow’s must-have skills
- Foster a diverse and inclusive workplace

- Maintain the injury frequency rate at less than or equal to 3.5%
- Increase every other year employee satisfaction as measured by well-being survey
- 100% of employees will have followed training and e learning annually (excluding mandatory trainings by law) by 2030
- Include all employees in people review program



GOVERNANCE

- Deploy a committed corporate responsibility governance
- Integrate sustainability as a shared value across our organization
- Integrate environmental criteria in our risk management processes
- Implement a responsible procurement policy
- Maintain high standards by conducting business with integrity

- 100% of key third parties considered as critical from a compliance standpoint will be assessed for their integrity in conducting business
- Expand each year the coverage of corporate responsibility assessments of our active supplier database

Products & portfolio



Our products

Stallergenes Greer supports physicians specialised in allergy and patients at each stage of allergen immunotherapy (AIT) treatment. Our comprehensive and consistent portfolio is adapted to the individual needs and profile of each patient and covers a broad variety of allergens.

Spanning source materials, routes of administration, cutting-edge delivery mechanisms and finished products, Stallergenes Greer’s innovative diagnostic tools and AIT solutions are designed to improve ease of access and treatment outcomes.

Whatever the options, Stallergenes Greer’s diagnostic and AIT treatments meet the most stringent clinical criteria, quality standards and health authorities’ regulatory requirements.

Not all our products and extracts are available in all geographic territories.

A personalised and standardised treatment offering

Stallergenes Greer believes one solution does not fit all patients, hence we provide patients with personalised treatment options that are tailored to their individual needs. We aim to offer a comprehensive portfolio of AIT treatments globally which allow patients and their physicians to determine the administration method that best meets the disease and lifestyle needs of the patient.

The Group’s allergen extracts cover a vast array of allergens. They can be produced in standardised form and can also be tailored to the specific needs of patients in terms of composition, concentration, and dosage.

These personalised solutions, known as named patient products (NPPs), are prepared according to the physician’s prescription and the patient profile using a stock solution obtained via the extraction of allergens (pollens, house dust mites, moulds...).

Each NPP has its own biological activity and is prepared for the unique needs of an individual patient.

Respiratory allergy

Sublingual

Staloral® (oral solution), for the treatment of allergy involving rhinitis, conjunctivitis, rhino conjunctivitis or asthma (mild to moderate) of a seasonal or perennial nature, in adults and children (from the age of 5).

Actair®/ Orylmyte®/ Aitmyte® (tablet), for the treatment of house dust mite allergies involving rhinitis, with or without conjunctivitis, in adults and adolescents over the age of 12 (and under 12 years of age in certain territories).

Oralair®/ Aitgrys® (tablet), for the treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents, and children (above the age of 5). Oralair® is a five grass (cocksfoot, sweet vernal grass, rye grass, meadow grass, and timothy) mixture, which represents many of the natural exposure and sensitisation conditions of grass pollen allergic patients.

Subcutaneous

Alustal®, for the treatment of allergic rhinitis, allergic rhinoconjunctivitis or mild to moderate asthma in adults and children (from the age of 5).

Food allergy

Oral immunotherapy

Palforzia®, for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Use of Palforzia® may be continued in patients 18 years of age and older. Palforzia® is not indicated for the emergency treatment of allergic reactions, including anaphylaxis, and must always be used in conjunction with a peanut-avoidant diet.

Venom allergy

Subcutaneous

Albey® venom, for the treatment of allergy to wasp, honeybee, and yellow jacket venoms.

Extracts and supplies

Stallergenes Greer manufactures a broad portfolio of allergen extracts and diagnostic tests.

Veterinary use

From allergen testing to making precision treatment medicines, Stallergenes Greer is committed to providing veterinary specialists with products that can help treat animal allergies.

In the U.S., Stallergenes Greer offers a comprehensive range of allergen extracts and supplies for veterinary dermatologists to support the needs of their clients and pet patients.

Veterinary dermatologists are veterinarians that have specialised training in the management of allergic disease. They may use products from companies like Stallergenes Greer to compound named patient allergy products for dogs, cats, horses, and more.

Stallergenes Greer produces extracts of different strengths and formulations specifically for veterinary specialists.

Our portfolio

PRODUCTS AND PORTFOLIO

1/ SUBLINGUAL PRODUCTS

The allergens and concentrations available vary by market.

Allergens:

MITES
D.pteronyssinus
D. Farinae
D.pt / D.far 50/50
Blomia / D.pt / D.far

GRASSES
5 Grasses
Cocksfoot
Timothy
Bermuda Grass

TREES
Birch
Ash
Alder
Hazel
Olive
2 Trees Mix (Ash / Olive)
3 Trees Mix
(Alder / Birch / Hazel)
Cupressaceae
Birch / Timothy Mix

DANDER
Cat epithelia
Cat IR300

WEEDS
Ragweed
Wall pellitory
Mugwort

MOULDS
Alternaria

POLLIN MIX
Birch / Ash
5 Grasses / Olive
5 Grasses / Birch
5 Grasses / Rye
5 Grasses / Juniperus
5 Grasses / Ash
5 Grasses / Berm. Grass
5 Grasses / 3 trees
5 Grasses / Ragweed
Birch / Timothy
Olive / Ash
Cupressaceae / Olive
Birch / Olive
Ragweed / Mugwort
5 Grasses / Mugwort
5 Grasses / Cynodon

ORALAIR®/ AITGRYS®

A five grass pollen mixture composed of Cocksfoot (*Dactylis glomerata* L.), Sweet vernal grass (*Anthoxanthum odoratum* L.), Rye grass (*Lolium perenne* L.), Meadow grass (*Poa pratensis* L.) and Timothy (*Phleum pratense* L.).

ACTAIR®/ ORYLMYTE®/ AITMYTE®

A house dust mite (*Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*) mixture.

2/ ORAL IMMUNOTHERAPY

PALFORZIA®

A defatted powder of *Arachis hypogaea* L., semen (peanuts).

3/ SUBCUTANEOUS PRODUCTS

ALUSTAL®

ALBEY VENOM**

4/ VETERINARY PRODUCTS

VET EXTRACTS

Allergens:

TREES & SHRUBS
Acacia
Alder, Hazel
Alder, Red
Alder, White
Ash, Arizona
Ash, Oregon
Ash, Red/Green
Ash, White
Aspen
Bayberry/Was Myrtle
Beech, American
Birch, Black/Sweet
Birch, River
Birch, Spring
Birch, White
Box Elder
Cedar, Mountain
Cedar, Red
Cedar, Salt/Tamarisk
Cottonwood, Black
Cottonwood, Eastern
Cottonwood, Fremont
Cottonwood, Western
Cypress, Arizona
Cypress, Bald
Elm, American
Elm, Cedar/Fall Blooming
Elm, Siberian
Eucalyptus
Hackberry
Hazelnut, American
Hickory, Shagbark
Hickory, Shellbark
Hickory, White
Juniper, Oneseed
Juniper, Pinchot
Juniper, Rocky Mountain
Juniper, Utah
Juniper, Western
Locust Blossom, Black
Mango Blossom
Maple, Red
Maple, Silver/Soft
Maple, Sugar/Hard
Melaleuca

Mesquite
Mulberry, Paper
Mulberry, Red
Mulberry, White
Oak, Arizona/Gambel
Oak, Black
Oak, Bur
Oak, California Black
Oak, California Live
Oak, California White
Oak, Post
Oak, Red
Oak, Virginia Live
Oak, Water
Oak, Western White
Oak, White
Olive
Olive, Russian
Orange Pollen
Palm, Queen
Pecan
Pepper Tree
Pine, Australian (Beefwood)
Pine, Loblolly
Pine, Longleaf
Pine, Ponderosa
Pine, Virginia/Scrub
Pine, Eastern White
Pine, Western White
Pine, Yellow
Poplar, Lombardy
Poplar, White
Privet, Common
Sycamore, American/
Eastern
Sycamore, Western
Walnut, Black
Walnut, California Black
Walnut, English
Willow, Arroyo
Willow, Black
2 Maple Mix
3 Maple Mix
11 Tree Mix
Ash Mix
Birch Mix
Eastern 6 Tree Mix
Eastern 7 Tree Mix
Eastern 8 Tree Mix
Eastern 10 Tree Mix
Eastern Oak Mix
Elm Mix
Hickory Mix
Hickory-Pecan Mix
Maple-Box Elder Mix
Pine Mix
Western 10 Tree Mix
Western Oak Mix
Western Walnut Mix
Wheat Ox-Eye
Dandelion
Sunflower
Alfalfa
Mustard
Red Clover
Sugar Beet

WEEDS
Allscale
Baccharis
Burrobrush
Careless Weed, Amaranth/
Green
Cocklebur
Dock, Yellow/Curly
Dog Fennel
Firebush/Kochia
Juniper, Utah
Juniper, Western
Locust Blossom, Black
Mango Blossom
Maple, Red
Maple, Silver/Soft
Marsh Elder, Burweed/Giant
Poverty

Marsh Elder, True/Rough
Mugwort, Common
Mugwort, Darkleaved/
Sagebrush, Prairie
Nettle
Palmer's Amaranth
Pigweed, Rough/Redroot
Plantain, English
Rabbit Bush
Ragweed, Desert
Ragweed, False
Ragweed, Giant
Ragweed, Short
Ragweed, Slender
Ragweed, Southern
Ragweed, Western
Russian Thistle
Sagebrush, Common
Saltbush, Annual
Sorrel, Sheep/Red
Wingscale
3 Weed Mix
Dock-Sorrel Mix
Pigweed Mix
Plantain-Sorrel Mix
Ragweed Mix
Sage Mix
Scale/Atriplex Mix
Western Ragweed Mix

GRASSES
Bahia Grass
Bermuda
Brome Grass, Smooth
Canarygrass
Corn, Cultivated
Couch/Quack Grass
Johnson Grass
Kentucky Blue/June
Meadow Fescue
Oats, Common/Cultivated
Orchard
Redtop

RYE, CULTIVATED
Ryegrass, Giant Wild
Ryegrass, Italian
Ryegrass, Perennial
Sweet Vernal
Timothy
Velvetgrass
Wheat Cultivated
Wheatgrass, Western
7 Grass Mix
9 Southern Grass Mix
Bermuda-Johnson Grass
Mix
K-O-R-T Grass Mix

FUNGI & SMUTS
Acremonium strictum
Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans
Chaetomium globosum
Cladosporium herbarum
Cladosporium
phaeospermum
Drechslera spicifera
Epicossum nigrum
Epidermophyton floccosum
Fusarium solani
Geotrichum candidum
Gliocladium viride
Helminthosporium solani
Malassezia pachydermatis
Mucor circinelloides f.
circinelloides

Mucor circinelloides f.
lusitanicus
Mucor plumbeus
Neurospora intermedia
Paecilomyces variotii
Penicillium chrysogenum
(notatum)
Penicillium digitatum
Phoma betae
Rhizopus oryzae
Rhizopus stolonifer
Rhodotorula mucilaginosa
var. mucilaginosa
Saccharomyces cerevisiae
Stemphylium solani
Trichoderma harzianum
Trichophyton
mentagrophytes
Trichophyton rubrum
Trichothecium roseum
Aspergillus Mix
Dematiaceae Mix
Fusarium Mix
Mold Mix #1
Mold Mix #2
Mold Mix #3
Monilia Mix
Mucor mix
Penicillium Mix
Phycomycetes Mix
Rhizopus Mix
Corn Smut
Grain Smut mix
Grass Smut Mix

EPITHELIA
Cat Epithelia
Cattle Epithelia
Dog Epithelia
Gerbil Epithelia
Goat Epithelia
Guinea Pig Epithelia
Hamster Epithelia
Hog Epithelia
Horse Epithelia
Human Dander
Mouse Epithelia
Rabbit Epithelia
Rat Epithelia
Sheep Epithelia

FEATHERS & MISCELLANEOUS INHALANTS
Canary Feathers
Chicken Feathers
Duck Feathers
Parakeet Feathers
Feather Mix
Cotton Linters
Cottonseed
Flaxseed
Kapok Seed
Orris Root
Pyrethrum
Silk
Tobacco Leaf

INSECTS
Ant, Black/Carpenter
Ant, Fire – Solenopsis richteri
Ant, Fire – Solenopsis invicta
Cockroach, American
Cockroach, German
Culicoids
Deer Fly
Flea
Horse Fly
House Fly
Mosquito
2 Cockroach Mix
4 Insect Mix

DUST & DUST MITES
Dust, House
Grain Mill Dust Mix
Acarus siro
Blomia tropicalis
Dermatophagoides farinae
Dermatophagoides pteronyssinus
Lepidoglyphus destructor
Tyrophagus putrescentiae
Equal Parts Mixture

VET OTHER SUPPLIES

STERILE DILUENTS

NONSTERILE EMPTY VIALS

STERILE EMPTY VIALS

PLASTIC COLORED CAPS

VIAL RACKS

AMBER VIALS AND METERED PUMPS

SYRINGES AND SYRINGE TRAYS

ANCILLARY PRODUCTS

5/ STANDARDISED HUMAN EXTRACTS

STANDARDISED CAT HAIR

STANDARDISED DERMATOPHAGOIDES FARINA MITE

STANDARDISED DERMATOPHAGOIDES PTERONYSSINUS MITE

STANDARDISED MITE MIX

STANDARDISED GRASS & POLLENS

Bermuda Grass
Kentucky Blue/June
Meadow Fescue
Orchard
Redtop
Ryegrass, Perennial
Sweet Vernal
Timothy
7 Grass Mix
K-O-R-T Grass Mix
K-O-R-T and Sweet Vernal Mix
K-O-T Grass Mix
Timothy/Orchard Grass Mix
T-O-S Grass Mix
Ragweed, Short
National Weed Mix
Ragweed Mix

POLLENS -TREES & SHRUBS

Acacia
Alder, Hazel
Alder, Red
Alder, White
Ash, Arizona (Velvet)
Ash, Green
Ash, Oregon
Ash, White
Aspen
Beech, American
Birch, Black/Sweet
Birch, River

Birch, Spring
Birch, White
Box Elder
Cedar, Mountain
Cedar, Red
Cedar, Salt (Tamarisk)
Cottonwood, Arizona (Fremont)
Cottonwood, Black
Cottonwood, Eastern
Cottonwood, Western
Cypress, Bald
Elm, American
Elm, Cedar
Elm, Siberian
Eucalyptus, Bluegum
Hackberry
Hazelnut, American
Hickory, Shagbark
Hickory, Shellbark
Hickory, White
Juniper, Oneseed
Juniper, Pinchot
Juniper, Rocky Mountain
Juniper, Utah
Juniper, Western
Locust Blossom, Black
Mango Blossom
Maple, Red
Maple, Silver/Soft
Maple, Sugar/Hard
Melaleuca
Mesquite, Velvet
Mulberry, Paper
Mulberry, Red
Mulberry, White
Oak, Arizona (Gambel)
Oak, Black
Oak, Bur
Oak, California Black
Oak, California Live
Oak, California White
Oak, Post
Oak, Red
Oak, Virginia Live
Oak, Water
Oak, Western White
Oak, White
Olive
Olive, Russian
Orange Pollen
Pecan
Pepper Tree
Pine, Australian (Beefwood)
Pine, Loblolly
Pine, Longleaf
Pine, Ponderosa
Pine, Virginia/Scrub
Pine, Eastern White
Pine, Western White
Pine, Yellow
Poplar, Lombardy's
Poplar, White
Privet
Sweetgum
Sycamore, American
Sycamore, California (Western)
Walnut, Black
Walnut, California Black
Walnut, English
Wax Myrtle
Willow, Arroyo
Willow, Black
2 Maple Mix
3 Maple Mix
11 Tree Mix
Birch Mix
Central/Eastern 4 Tree Mix
Eastern 6 Tree Mix
Eastern 7 Tree Mix
Eastern 8 Tree Mix
Eastern 9 Tree Mix
Eastern 10 Tree Mix
Eastern Oak Mix
Elm Mix
Hickory Mix
Hickory-Pecan Mix
Juniper Mix
Maple-Box Elder Mix
Peppertree Mix
Pine Mix
Western 3 Tree Mix
Western 10 Tree Mix

Western Oak Mix
Western Walnut Mix

POLLENS – FLOWERS & PLANTS

Daisy
Dandelion
Sunflower
Alfalfa
Rape (Mustard)
Red Clover
Sugar Beet

POLLENS - WEEDS

Allscale
Amaranth, Green
Burningbush (Kochia)
Burrobrush
Cocklebur
Dock, Yellow (Curly)
Dogfennel
Goldenrod
Iodinebush
Lamb's Quarters
Lenscale (Quailbrush)
Marshelder, Burweed (Giant Poverty)
Marshelder, True (Rough)
Mugwort, Common
Nettle
Palmer's Amaranth
Pigweed, Rough Redroot
Pigweed, Spiny
Plantain, English
Rabbit Bush
Ragweed, Desert
Ragweed, False
Ragweed, Giant (Tall)
Ragweed, Lanceleaf
Ragweed, Slender
Ragweed, Western
Russian Thistle
Sagebrush, Common
Sage, Prairie
Saltbush, Annual
Sorrel, Sheep (Red)
Waterhemp, Tall
Wingscale
3 Weed Mix
Baccharis Mix
Central/Western Weed Mix
Common Weed Mix
Dock-Sorrel Mix
Pigweed Mix
Plantain-Sorrel Mix
Sage Mix
Scale/Atriplex Mix
Western Ragweed Mix

POLLENS - GRASSES

Brome, Smooth
Canary Grass, Reed
Corn, Cultivated
Johnson Grass
Oats, Cultivated
Quack (Couch) Grass
Rye, Cultivated
Ryegrass, Giant Wild
Ryegrass, Italian
Velvetgrass
Wheat, Cultivated
Wheatgrass, Western

MOULDS

Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans*
Chaetomium globosum
Cladosporium herbarum
Cladosporium phaeospermum
Epicossum nigrum
Epidermophyton floccosum
Fusarium solani
Geotrichum candidum
Gliobellera fujikuroi
Gliocladium viride
Helminthosporium solani

Cabbage
Cantaloupe
Carrot
Cauliflower
Celery
Cherry, Sweet
Cacao Bean
Cinnamon
Coffee
Corn
Cranberry
Cucumber
Garlic
Ginger
Grape, White Seedless
Grapefruit
Hops
Lemon
Lettuce
Malt
Mushroom
Mustard Seed
Nutmeg
Oat
Olive, Green
Onion
Orange
Pea, Green or English
Peach
Pear
Pepper, Black
Pepper, Green
Pineapple
Potato, Sweet
Potato, White
Raspberry, Red
Rice
Rye
Sesame Seed
Soybean
Spinach
Squash, Yellow Summer
Strawberry
Tomato
Vanilla
Watermelon
Wheat, Whole
Beef
Lamb
Pork
Chicken Meat
Egg White, Chicken
Egg Whole, Chicken
Egg Yolk, Chicken
Turkey Meat
Milk, Cow
Bass, Black
Catfish, Channel
Clam, Northern Quahog
Cod, Atlantic
Crab, Blue
Flounder, Southern
Lobster, American
Mackerel, King/Atlantic
Oyster, Atlantic/Eastern
Perch, Ocean
Salmon, Atlantic
Scallops, Sea
Shrimp, Brown
Trout, Rainbow
Tuna, Yellowfin
Fish, Mix
Shellfish Mix
Almond
Brazil Nut
Cashew Nut
Coconut
Hazelnut (Filbert)
Peanut
Pecan
Walnut, Black
Walnut, English

GREER® PICK®
GREER® PICK® TRAY™
GREER® PICK® TRAY™
LID PRICK LANCET®
STALLERPOINT®
GREER® PICK® WELL™
SKINTESTOR OMNI™
SKINTESTOR OMNI™ SYSTEM
SKINTESTOR OMNI™ TRAYS
THE GREER® PICK® SYSTEM

6/ OTHER SUPPLIES
DOM' HOUS®
GREER® STERILE DILUENTS™
GREER® STERILE EMPTY VIALS™
GREER® VERSA VIAL RACK

ANCILLARY PRODUCTS

GREER PHARMACY – NAMED PATIENT PRODUCTS

JIFFY MAILING BAGS

MAILING CONTAINERS

NONSTERILE EMPTY VIALS

PLASTIC COLOURED CAPS

SAFETY SYRINGES

STERILE DILUENTS

SHARPS COLLECTORS

SKIN REACTION GUIDES

STERILE EMPTY VIALS

STOCK AND CUSTOM-PRINTED LABELS

STYROFOAM CONTAINERS

SYRINGES AND SYRINGE TRAYS

VIAL RACKS

5/ PRICK TESTS

40-WELL SKIN OMNI™ EVALUATION PACKAGE

40-WELL GREER® PICK® EVALUATION PACKAGE

60-WELL GREER® PICK® EVALUATION PACKAGE

60-WELL SKIN OMNI™

EVALUATION PACKAGE

60-WELL GREER® PICK® EVALUATION PACKAGE

ALYOSTAL PRICK®

Positive control (Histamin)

Negative control

D. Pteronyssinus

D. Farinae

5 Grasses

Birch

Ragweed

Hazel

Olive

Cupressacee

Cat dander

Mugwort

Alder

Ash

Wall pellitory

Blomia

Cynodon

Rye grass

Alternia

Artemisia

Bermuda grass

Latex

**STALLERGENES GREER
INTERNATIONAL AG**
Zugerstrasse 76b
6340 Baar, Switzerland

This report contains information about Stallergenes Greer’s worldwide business. Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice.

2023 *In Review* is available on the Group’s website **www.stallergenesgreer.com**

CONCEPTION AND EDITORIAL FOLK FORMAN, 68 rue de la Chaussée d’Antin, 75009 Paris, FRANCE
www.folkforman.com

CREATION AND PRODUCTION MPG VISUAL DESIGN, PO Box 1002, Manzanita, OR 97130, USA
www.mpgvisualdesign.com

PHOTO CREDITS All rights reserved - Anthony Voisin (cover, p 4, 6, 11, 14, 16, 17, 18, 20, 27, 29, 32, 34, 36, 38, 41, 45, 53, 60, 65) - Rusty Williams (p 55) - Jeanyves Verdu (p 13, 60, 61) - Getty Images (p 13, 56) - Adobe Stock (p 22, 24, 42, 46, 50, 59).



Printed in France by Noël Imprimeur Paris - Imprim’Vert® certified printer - on paper from sustainable forests in an ISO 14001 and EMAS certified facility.

Completed May 28, 2024

Thank you to all patients, healthcare professionals and Stallergenes Greer employees who appear in this publication.

Cover: Amine Behadada, Production Team Manager, Manufacturing Unit 2, France | Page 55: Miguel Corella, Quality Assurance Manager, U.S.

Palforzia®: © 2023, Société des Produits Nestlé S.A. or its affiliates.

All other product names listed in this document are registered trademarks of the Stallergenes Greer group.

Produced by Stallergenes Greer, Global Communications

Follow us on



www.linkedin.com/company/stallergenesgreer



x.com/StallergenesCom

**STALLERGENES GREER
INTERNATIONAL AG**

Zugerstrasse 76b
6340 Baar, Switzerland